Beam Therapeutics Inc. (BEAM) |
|
30.39 0.05 (0.16%)
|
03-24 16:00 |
|
Open: |
30.12 |
Pre. Close: |
30.34 |
|
High:
|
30.83 |
Low:
|
29.59 |
|
Volume:
|
739,777 |
Market Cap:
|
2,324(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:20 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 44.4  One year: 50.49 |
| Support: |
Support1: 29.59 Support2: 24.61 |
| Resistance: |
Resistance1: 38.01 Resistance2: 43.22 |
| Pivot: |
33.85 |
| Moving Average: |
MA(5): 31.2 MA(20): 35.17
MA(100): 41.67 MA(250): 45.65 |
| MACD: |
MACD(12,26): -2.8 Signal(9): -2.5 |
| Stochastic oscillator: |
%K(14,3): 6.1 %D(3): 9.8 |
| RSI: |
RSI(14): 29.9  |
| 52-week: |
High: 73.26 Low: 27.77 |
| Average Vol(K): |
3-Month: 916 (K) 10-Days: 1,091 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BEAM ] has closed above bottom band by 15.2%. Bollinger Bands are 6.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
30.87 - 31.05 |
31.05 - 31.21 |
|
Low:
|
29.14 - 29.36 |
29.36 - 29.57 |
|
Close:
|
30.06 - 30.39 |
30.39 - 30.69 |
|
Company Description |
|
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. |
Headline News |
Mon, 27 Mar 2023
William Blair Weighs in on Beam Therapeutics Inc.'s Q1 2023 ... - MarketBeat
Fri, 24 Mar 2023
Chutes & Ladders—Ex-Seagen CEO takes new role less than a year ... - FierceBiotech
Tue, 21 Mar 2023
Beam Therapeutics (NASDAQ:BEAM) Research Coverage Started ... - MarketBeat
Tue, 21 Mar 2023
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief ... - GlobeNewswire
Wed, 15 Mar 2023
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference - Marketscreener.com
Mon, 13 Mar 2023
January 2024 Options Now Available For Beam Therapeutics - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
72 (M) |
| Shares Float |
64 (M) |
|
% Held by Insiders
|
1.7 (%) |
|
% Held by Institutions
|
86.5 (%) |
|
Shares Short
|
12,480 (K) |
|
Shares Short P.Month
|
12,420 (K) |
Stock Financials |
|
EPS
|
-4.06 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
10.53 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-555.7 |
|
Return on Assets (ttm)
|
-15.1 |
|
Return on Equity (ttm)
|
-33.4 |
|
Qtrly Rev. Growth
|
-60.8 |
|
Gross Profit (p.s.)
|
-3.47 |
|
Sales Per Share
|
0.84 |
|
EBITDA (p.s.)
|
-4.48 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
23 (M) |
|
Levered Free Cash Flow
|
138 (M) |
Stock Valuations |
|
PE Ratio
|
-7.49 |
|
PEG Ratio
|
-1.6 |
|
Price to Book value
|
2.88 |
|
Price to Sales
|
36.11 |
|
Price to Cash Flow
|
97.65 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
